Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia

Critical Care Medicine

Volumn 28, Issue 5, 2000, Pages 1276-1282

  Grobmyer, Stephen R ^a   Barie, Philip S ^a   Nathan, Carl F ^a   Fuortes, Michele ^a   Lin, Edward ^b   Lowry, Stephen F ^b   Wright, Clifford D ^c   Weyant, Michael J ^a   Hydo, Lynn ^a   Reeves, Faith ^a   Shiloh, Michael U ^a   Ding, Aihao ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c AMGEN INC   (United States)

Author keywords

Cytokines; Endotoxin; Human; Interleukin 6; Interleukin 10; Lipopolysaccharide; Neutrophils; Protease inhibitor; Sepsis; Tumor necrosis factor

Indexed keywords

HYDROGEN PEROXIDE; INTERLEUKIN 10; INTERLEUKIN 6; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTOXEMIA; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPSIS; SURGICAL PATIENT; TISSUE INJURY;

EID: 0034075048     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200005000-00003     Document Type: Review

References (35)

1. 1. Bone RC, Fisher CJ, Clemmer TP, et al: A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
2. 2. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
3. 3. Fry DE, Pearlstein R, Fulton RL, et al: Multiple system organ failure: The role of uncontrolled infection. Arch Surg 1980; 115: 136-140
4. 4. Barie PS, Hydo LJ, Fischer E: A prospective comparison of two multiple organ dysfunction/failure scoring systems for prediction of mortality in critical surgical illness. J Trauma 1994; 37:660-666
5. 5. Barie PS, Hydo LJ, Fischer E: Development of multiple organ dysfunction syndrome in critically ill patients with perforated viscus. Predictive value of APACHE severity scoring. Arch Surg 1996; 131:37-43
6. 6. Astiz ME, Rackow EC: Septic shock. Lancet 1998; 351:1501-1505
7. 7. van Bebber IP, Boekholz WK, Goris RJ, et al: Neutrophil function and lipid peroxidation in a rat model of multiple organ failure. J Surg Res 1989; 47:471-475
8. 8. Botha AJ, Moore FA, Moore EE, et al: Early neutrophil sequestration after injury: A pathogenic mechanism for multiple organ failure. J Trauma 1995; 39:411-417
9. 9. Patrick DA, Moore FA, Moore EE, et al: Neutrophil priming and activation in the pathogenesis of postinjury multiple organ failure. New Horizons 1996; 4:194-210
10. 10. Nathan CF: Neutrophil activation on biological surfaces: Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987; 80:1550-1560
11. 11. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-376
12. 12. Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor: A potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986; 83: 6692-6696
13. 13. Ohlsson K, Bergenfeldt M, Bjork P: Functional studies of human secretory leukocyte protease inhibitor. Adv Exp Med Biol 1988; 240:123-131
14. 14. Rice WG, Weiss SJ: Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 1990; 249:178-181
15. 15. Jin FT, Nathan C, Radzioch D, et al: Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88: 417-426
16. 16. Bohm B, Aigner T, Kinne R, et al: The serine-protease inhibitor of cartilage matrix is not a chondrocytic gene product. Eur J Biochem 1992; 207:773-779
17. 17. Jin F, Nathan CF, Radzioch D, et al: Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor: A macrophage-derived lipopolysaccharide inhibitor. Infect Immun 1998; 66: 2447-2452
18. 18. Zhang Y, Dewitt DL, McNeely TB, et al: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99:894-900
19. 19. Mulligan MS, Desrochers PE, Chinnaiyan AM, et al: In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci U S A 1993; 90:11523-11527
20. 20. Hiemstra PS, Maassen RJ, Stolk J, et al: Antibacterial activity of antileukoprotease. Infect Immun 1996; 64:4520-4524
21. 21. van der Poll T, Coyle SM, Barbosa K, et al: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin-10 production during human endotoxemia. J Clin Invest 1996; 97:713-719
22. 22. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
23. 23. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
24. 24. Eisenberg SP, Hale KK, Heimdal P, et al: Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990; 265:7976-7981
25. 25. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
26. 26. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
27. 27. Barriere SL, Lowry SF: An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376-393
28. 28. Calvano SE, van der Poll T, Coyle SM, et al: Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg 1996; 131:434-437
29. 29. Marchant A, Alegre ML, Hakim A, et al: Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15:266-273
30. 30. Kida K, Mizuuchi T, Takeyama K, et al: Serum secretory leukoprotease inhibitor levels to diagnose pneumonia in the elderly. Am Rev Respir Dis 1992; 146:1426-1429
31. 31. Fryksmark U, Prellner T, Tegner H, et al: Studies on the role of antileukoprotease in respiratory tract diseases. Eur J Respir Dis 1984; 65:201-209
32. 32. Spinas GA, Kelly U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 1992; 90:533-536
33. 33. van der Poll T, de Waal Malefyt R, Coyle SM, et al: Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble IL-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175:118-122
34. 34. Bergenfeldt M, Bjork P, Ohlsson K: The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest 1990; 50:729-737
35. 35. Nathan C, Xie QW, Halbwachs ML, et al: Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of CD43 (sialophorin, leukosialin). J Cell Biol 1993; 122:243-256